MICROBA LIFE SCIENCES LIMITED (MAP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MAP - MICROBA LIFE SCIENCES LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.07
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.16

21 Nov
2024

-0.010

OPEN

$0.17

-5.88%

HIGH

$0.17

105,430

LOW

$0.16

TARGET
$0.34 112.5% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MDC . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
MAP: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 4.9 - 3.2 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 24/06 - (franking Ex-Di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 20202021202220232024
EPS Basic xxxxxxxxxxxx-4.9
DPS All xxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxx12.1 M
Book Value Per Share xxxxxxxxxxxx9.2
Net Operating Cash Flow xxxxxxxxxxxx-15.6 M
Net Profit Margin xxxxxxxxxxxx-164.92 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20202021202220232024
Return on Capital Employed xxxxxxxxxxxx-49.98 %
Return on Invested Capital xxxxxxxxxxxx-49.60 %
Return on Assets xxxxxxxxxxxx-37.98 %
Return on Equity xxxxxxxxxxxx-49.98 %
Return on Total Capital xxxxxxxxxxxx-64.94 %
Free Cash Flow ex dividends xxxxxxxxxxxx-17.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20202021202220232024
Short-Term Debt xxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxx8 M
Cash & Equivalents - Generic xxxxxxxxxxxx21 M
Price To Book Value xxxxxxxxxxxx1.74

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20202021202220232024
Capex xxxxxxxxxxxx4.4 M
Capex % of Sales xxxxxxxxxxxx36.22 %
Cost of Goods Sold xxxxxxxxxxxx21 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxx18 M
Research & Development xxxxxxxxxxxx11 M
Investments - Total xxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

01/11/2024

1

Speculative Buy

$0.35

118.75%

Microba Life Sciences reported 1Q25 revenue, which was in line with Bell Potter's expectations, including organic growth in testing business from a relatively low base and slight declines in Invivo, the acquired business. 

The analyst highlights 1Q is typically the most subdued for the company with an expected ramp up in both MetaXplore and MetaPanel in Australia for FY25.

First sales of MetaXplore were achieved in Oct as the company begins to maximise the commercial infrastructure acquired with Invivo.

Unchanged Speculative Buy rating and 35c target price.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -3.20 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -3.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

04/11/2024

1

Speculative Buy

$0.44

175.00%

Canaccord Genuity notes Microba Life Sciences' 1Q25 revenue was $3.65m, down from the prior quarter due to seasonality, though October showed record sales, driven by its MetaXplore and MetaPanel diagnostics.

The partnership with Sonic is expected to boost test referrals among clinicians, with significant growth anticipated as reimbursement opportunities develop. Cash on hand is $16.4m, supporting near-term growth.

The Speculative Buy rating and target price of 44c are retained.
Access Extra Coverage Research History >

MAP STOCK CHART

FNArena News on MAP

1
Australian Broker Call *Extra* Edition – Nov 04, 2024

Nov 04 2024 - Daily Market Reports
2
FNArena Corporate Results Monitor – 02-09-2024

Sep 02 2024 - Australia
3
FNArena Corporate Results Monitor – 29-02-2024

Feb 29 2024 - Australia
4
Australian Broker Call *Extra* Edition – Dec 18, 2023

Dec 18 2023 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Oct 26, 2023

Oct 26 2023 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
2
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
3
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
4
CSL Shares Breaking Free

Jul 23 2024 - Technicals
5
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
6
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
7
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
8
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
9
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
10
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps